- Nektar Therapeutics (NKTR, Financial) will present top-line data from the Phase 2b REZOLVE-AD study on June 24, 2025.
- The study focuses on rezpegaldesleukin for treating moderate-to-severe atopic dermatitis.
- An investor call and webcast are scheduled for 8:15 AM ET with a replay available for 30 days.
Nektar Therapeutics (NKTR), a clinical-stage biotechnology company, is set to reveal top-line results from the 16-week induction period of its Phase 2b REZOLVE-AD study, which evaluates the effectiveness of rezpegaldesleukin, a regulatory T-cell proliferator, in treating moderate-to-severe atopic dermatitis. The announcement will be made during an investor call and webcast on June 24, 2025, at 8:15 AM ET.
The data is anticipated to be released via a morning press release, with details on accessing the live webcast made available through Nektar's website. Moreover, a replay of the webcast will be accessible for at least 30 days following the event, ensuring ample opportunity for stakeholders to review the findings.
Nektar Therapeutics, headquartered in San Francisco, California, focuses on innovative immunology therapies addressing autoimmune and chronic inflammatory diseases. The company's lead product, rezpegaldesleukin (REZPEG or NKTR-358), is under evaluation in two Phase 2b trials, with another study targeting alopecia areata. Investors and interested parties are encouraged to visit www.nektar.com for more information.
